Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03123393
Title TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | GBR | FRA | ESP | CAN


No variant requirements are available.